We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Rheumatoid Arthritis Drug Could Be Repurposed To Treat COVID-19 Patients

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

A drug against rheumatoid arthritis called baricitinib could potentially be repurposed to treat patients with COVID-19, according to a study conducted by an international research team including researchers at Karolinska Institutet in Sweden. The findings, published in the journal EMBO Molecular Medicine, represent an example of how artificial intelligence (AI)-algorithms could help identify existing drugs as potential therapies against as new illnesses.

Baricitinib is a once-daily oral drug used for treatment of adult patients with moderate to severe rheumatoid arthritis. It acts as an inhibitor of janus kinase, a type of enzyme that acts as an “on” or “off” switch in many cellular functions. The drug works by interfering with the inflammatory processes of the immune system and has been viewed as a potential treatment candidate for COVID-19.

In this study, the researchers used AI-algorithms to identify existing drugs capable of blocking both inflammation and infectivity. Baricitinib was identified as a promising repurposing candidate for COVID-19, due to its previously demonstrated ability to inhibit both cytokine activity and viral spread.

Lab tests and clinical pilot study


In test tubes and 3D-human miniature livers, the researchers showed that the drug inhibited signaling of cytokines, immune system-proteins known to overreact and drive inflammation in severe cases of COVID-19 infection. It also helped reduce the viral load of SARS-CoV-2, the virus that causes COVID-19, and the level of the signal molecule interleukin-6 (IL-6), a predictor of mortality from acute respiratory distress syndrome associated with COVID-19.

In addition to the lab tests, a small pilot study of three men and one woman with bilateral COVID-19 pneumonia was conducted in Milan, Italy. After 10-12 days of treatment with baricitinib, all four patients showed improvements in signs and symptoms such as cough, fever and reductions in viral load and plasma IL-6 levels.

May lower inflammation and viral load


“Collectively, these data suggest that baricitinib may lower inflammation and viral load in COVID-19,” says Ali Mirazimi, adjunct professor in the Department of Laboratory Medicine, Karolinska Institutet, who led the functional virus studies.

Additional trials of baricitinib are currently underway in 85 hospitalized COVID-19 patients across three hospitals in Northern and Central Italy, with encouraging initial results in patient outcomes, according to the researchers.

“We are integrating and carefully analyzing these trial data and providing functional and mechanistic follow-up studies to scrutinize baricitinib’s mode of action,” says Volker Lauschke, associate professor of personalized medicine and drug development at the Department of Physiology and Pharmacology, Karolinska Institutet, who led the functional testing of baricitinib.

The study was funded by Eli Lilly and Company and the Sacco Baricitinib Study Group. Several of the authors reported potential conflicts of interests, including employment and shareholdings in Eli Lilly and Company, which owns the trademark for the baricitinib drug Olumiant. For a full list of disclosures, please see the full article.

Reference: Stebbing, et al. (2020) Mechanism of Baricitinib Supports Artificial Intelligence-Predicted Testing in COVID-19 Patients. EMBO Molecular Medicine DOI: 10.15252/emmm.202012697

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.